Treatment arm | |||
---|---|---|---|
E–T–CMF | ET–CMF | Total | |
Patients | |||
N | 324 | 339 | 663 |
Age in years | |||
Mean (SD) | 54.2 (11.1) | 53.9 (11.3) | 54.0 (11.2) |
Min–Max | 29–79 | 22–76 | 22–79 |
N (%) | N (%) | N (%) | |
---|---|---|---|
Adjuvant hormonal therapy | |||
Yes | 234 (74.3) | 252 (77.3) | 486 (75.8) |
No | 81 (25.7) | 74 (22.7) | 155 (24.2) |
Not reported | 9 (2.8) | 13 (3.8) | 22 (3.3) |
Adjuvant radiotherapy | |||
Yes | 220 (71.0) | 260 (80.0) | 480 (75.6) |
No | 90 (29.0) | 65 (20.0) | 155 (24.4) |
Not reported | 14 (4.3) | 14 (4.1) | 28 (4.2) |
Age | |||
<50 | 117 (36.1) | 123 (36.2) | 240 (36.2) |
≥50 | 207 (63.9) | 216 (63.8) | 423 (63.8) |
EGFR protein expression | |||
Positive | 50 (15.9) | 46 (14.4) | 96 (15.2) |
Negative (<1%) | 264 (84.1) | 273 (85.6) | 537 (84.8) |
Not reported | 10 (3.1) | 20 (5.9) | 30 (4.5) |
ER/PgR status | |||
Negative | 84 (26.0) | 85 (25.1) | 169 (25.5) |
Positive | 239 (74.0) | 254 (74.9) | 493 (74.5) |
Not reported | 1 (0.3) | 1 (0.2) | |
Histological grade | |||
I–II | 154 (47.5) | 172 (50.8) | 326 (49.2) |
III-undifferentiated | 170 (52.5) | 167 (49.2) | 337 (50.8) |
HER2 protein expression | |||
Overexpression | 92 (29.3) | 103 (31.5) | 195 (30.4) |
No overexpression | 222 (70.7) | 224 (68.5) | 446 (69.6) |
Not reported | 10 (3.1) | 12 (3.5) | 22 (3.3) |
HER2 status (IHC/FISH) | |||
Negative | 241 (77.5) | 248 (77.3) | 489 (77.4) |
Positive | 70 (22.5) | 73 (22.7) | 143 (22.6) |
Not reported | 13 (4.0) | 18 (5.3) | 31 (4.7) |
Histological type | |||
Invasive ductal | 261 (80.6) | 268 (79.1) | 529 (79.8) |
Invasive lobular | 27 (8.3) | 37 (10.9) | 64 (9.6) |
Mixed | 22 (6.8) | 19 (5.6) | 41 (6.2) |
Other | 14 (4.3) | 15 (4.4) | 29 (4.4) |
Interval from operation | |||
<2 weeks | 27 (8.3) | 22 (6.5) | 49 (7.4) |
2–4 weeks | 144 (44.6) | 147 (43.5) | 291 (44.0) |
>4 weeks | 152 (47.1) | 169 (50.0) | 321 (48.6) |
Not reported | 1 (0.3) | 1 (0.3) | 2 (0.3) |
Menopausal status | |||
Pre | 137 (42.3) | 145 (42.8) | 282 (42.6) |
Post | 187 (57.7) | 194 (57.2) | 381 (57.4) |
Number of positive nodes | |||
1–3 | 143 (44.1) | 159 (46.9) | 302 (45.6) |
≥4 | 181 (55.9) | 180 (53.1) | 361 (54.4) |
Tumor size | |||
≤2 cm | 90 (27.8) | 107 (31.6) | 197 (29.8) |
>2 cm | 234 (72.2) | 232 (68.4) | 466 (70.2) |
Subtype classification | |||
Luminal A | 93 (30.5) | 97 (30.3) | 190 (30.4) |
Luminal B | 105 (34.4) | 112 (35.0) | 217 (34.7) |
Luminal-HER2 | 35 (11.5) | 44 (13.7) | 79 (12.6) |
HER2-enriched | 35 (11.5) | 29 (9.1) | 64 (10.3) |
Triple-negative | 37 (12.1) | 38 (11.9) | 75 (12.0) |
Not reported | 19 (5.9) | 19 (5.6) | 38 (5.7) |
Type of surgery | |||
Modified radical mastectomy | 219 (67.6) | 227 (67.0) | 446 (67.3) |
Breast-conserving | 105 (32.4) | 112 (33.0) | 217 (32.7) |